RecruitingNot ApplicableNCT06514495

Differential Effects of in Vivo and Virtual Exposure Therapy in Agoraphobia

Differential Effects of in Vivo and Virtual Exposure Therapy on the Interoception and Reactivity of Different Body Systems in Agoraphobia


Sponsor

Johannes Gutenberg University Mainz

Enrollment

68 participants

Start Date

May 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Anxiety disorders, including agoraphobia, are prevalent in the German population, leading affected individuals to avoid specific places like crowds or public transport. Although cognitive-behavioral therapy with exposure is an effective treatment, many patients resort to medication rather than therapy. Virtual Reality Exposure Therapy (VRET) shows promise in easing exposure treatment with customizable scenarios. Interoception (body symptom perception) and the endocannabinoid system are explored as factors in maintaining agoraphobia. Studies investigate how therapies like exposure (both in vivo and in VR) impact these factors and treatment outcomes. Interoception, especially in panic disorder patients, plays a crucial role, with accurate heartbeat perception linked to maintaining anxiety. The endocannabinoid system, affecting various functions, is studied for its role in therapy outcomes and its modulation of the body's stress response. The study aims to understand how these systems interact in agoraphobic patients and how therapy affects their functionality.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria4

  • Experimental group: Diagnosis of agoraphobia with or without panic disorder
  • Clinical control group: diagnosis of social phobia
  • Control group: healthy individuals without acute or chronic mental illness
  • A depressive disorder may be present as a comorbid diagnosis in the experimental group and the clinical control group

Exclusion Criteria5

  • Other mental illnesses: Substance dependence, schizophrenia, bipolar disorder, dementia, eating disorders, PTSD, major depressive episode, personality disorder
  • Somatic diseases: Cancer, cardiovascular diseases, epilepsy, autoimmune diseases, metabolic or endocrine diseases
  • Taking psychotropic medication (except antidepressants) or medication that affects the cardiovascular system (e.g. beta-blockers), medication containing cortisone, use of creams with corticosteroids
  • Pregnancy, breastfeeding
  • Ongoing psychotherapy

Interventions

OTHERTherapy

Cognitive behavioral psychotherapy with exposure


Locations(1)

University Medical Center

Mainz, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06514495


Related Trials